Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT00139139 |
| Other study ID # |
CDC-NCID-2643 |
| Secondary ID |
ASPHS196421/21 |
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
September 2003 |
| Est. completion date |
May 2005 |
Study information
| Verified date |
December 2021 |
| Source |
Centers for Disease Control and Prevention |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Immune globulin is effective about 85% of the time in preventing hepatitis A in people who
have been exposed, if it is given within 14 days of exposure. Several lines of evidence
suggest that hepatitis A vaccine might also be effective in this setting, and vaccine has the
advantage of providing long term protection. In this study, we compare how well immune
globulin and hepatitis A vaccine work in preventing clinical hepatitis A in household
contacts of persons with the disease. The study's hypothesis is that the the proportion of
exposed household contacts who receive hepatitis A vaccine within 14 days of exposure and
develop hepatitis A disease will be similar to the proportion of exposure household contacts
who receive immune globulin within 14 days of exposure and develop hepatitis A disease.
Description:
Title: An Epidemiologic Study of Hepatitis A Vaccine for Postexposure Prophylaxis Clinical
Phase: Investigation of an application unrelated to original approved use.
Primary Objective: To compare the clinical efficacy of vaccine and IG in the prevention of
confirmed hepatitis A disease when given within 14 days of exposure to a confirmed case of
hepatitis A disease.
Primary Hypothesis: The proportion of initially seronegative subjects who receive vaccine
within 14 days of exposure to an index case of hepatitis A disease and who have onset of a
confirmed case of hepatitis A disease within 56 days of exposure will be similar to the
proportion of initially seronegative subjects who receive IG within 14 days of exposure to an
index case and who have onset of a confirmed case of hepatitis A disease within 56 days of
exposure. The date of exposure is defined as the date of onset of clinical symptoms in the
index case.
(The statistical methods to examine this hypothesis require computing the relative risk, and
corresponding 90% confidence interval, of confirmed hepatitis A disease among those receiving
vaccine compared to those receiving IG, within 14 days of exposure. Inference of similarity
involves examining the upper bound of this confidence interval and translating this RR bound
into a lower bound of the 90% confidence interval for vaccine efficacy. Translation from
relative risk to efficacy depends on an assumption of the point estimate of the efficacy of
IG, based on historical data, the particular design of this study and assumptions regarding
how transmission of hepatitis A virus occurred in the study population.) Study Design and
Duration: Randomized, double-blinded, comparative, experimental epidemiologic study. Study
will be conducted among exposed contacts 2-40 years of age in the household exposure group
and is expected to last 18 months.
Sample Size: Enrollment will continue until 44 hepatitis A cases in randomized subjects are
observed. Assuming a 30% secondary attack rate in evaluable, confirmed contacts of index
cases and a 90% efficacy rate of IG, to observe 44 laboratory-confirmed cases of hepatitis A,
1468 randomized subjects will need to be evaluable (734/group). Evaluable is defined as
seronegative at baseline and with clinical follow-up data at Day 56. Assuming 90% of subjects
have follow-up data and 45% of subjects are seronegative at baseline, 4067 subjects ages 2 to
40 years must be randomized (2038/group). The actual enrollment may be different based on
validity of these assumptions.
Dosage and Route: Within an exposed group, subjects will be randomized to receive either
hepatitis A vaccine, VAQTA™, or immune globulin (IG) intramuscular (IM). Clinical material
will be administered by unblinded study personnel but subjects will not be told which
clinical material is being administered. The unblinded personnel will not be involved with
any other study procedures for that exposed group. Syringes will be masked to avoid any
possible chance at subject unblinding. The dose of VAQTA™ to be used will depend on the
subject's age. Persons 2 to 18 years of age will receive a 25-U dose of VAQTA™ administered
intramuscularly in the arm in a 0.5 mL volume. Persons 19 to 40 years of age and less than or
equal to 75 kg in weight will receive a 50-U dose of VAQTA™ administered intramuscularly in
the arm in a 1.0 mL volume. Persons 19 to 40 years of age and greater than 75 kg in weight
will receive a 50-U dose of VAQTA™ (administered as two 25-U doses) administered
intramuscularly with 0.5 mL in each arm. Persons 2 to 18 years of age will receive IG in one
arm; persons 19 to 40 years of age and less than or equal to 75 kg in weight will receive IG
in one arm; and persons 19 to 40 years of age and greater than 75 kg in weight will receive
IG with the total dose equally divided between each arm. All persons randomized to receive IG
will receive a dose of 0.02 mL/kg of body weight, up to a maximum of 1.5 mL for those less
than or equal to 75 kg in weight and 3.0 mL for those greater than 75 kg in weight. All
subjects less than or equal to 75 kg will receive 1 injection and only subjects 19 to 40
years of age and greater than 75 kg will receive 2 injections.
Efficacy Measurements: The primary measurement variable for efficacy is the proportion of
subjects with confirmed hepatitis A disease (hepatitis A IgM positive or serum or stool PCR
positive for HAV RNA and ALT twice the upper limit of normal with 1 or more of the clinical
signs/symptoms of hepatitis A disease).
Safety Measurements: Subjects will be evaluated for serious or unusual reactions throughout
the study period. The rate of serious adverse experiences in each group will be compared.
Data Analysis: In this study, efficacy comparisons will be made by estimation of the relative
risk of laboratory-confirmed clinical hepatitis A in the vaccine group compared to the IG
group. The relative risk is calculated as follows:
- where PV and PIG are the incidence rates of secondary cases of confirmed hepatitis A
disease in the vaccine and immune globulin treatment groups, respectively.
The primary analysis will be performed at the one-sided ɑ=0.05 level and examine the upper
bound of the 90% confidence for the relative risk of vaccine versus IG. A secondary efficacy
analysis will adjust for the exposure group in the estimation of the relative risk.
The sample size and power are based upon a fixed number of events design assuming equal
incidence rates in both the IG and vaccine populations and a one-sided significance level of
ɑ=0.05, and were calculated under the following testing hypotheses: Ho: PV / PIG ≥3.0 versus
Ha: PV / PIG <3.0. This is equivalent to testing that the upper bound of the 90% confidence
interval on the observed relative risk is <3.0. For a fixed accrual of 44 evaluable secondary
cases of confirmed hepatitis A, the study has 95% power to rule out a relative risk of 3.0 or
greater. If the total number of cases observed in this study is 44 and if no more than 27
(i.e., 61.4%) of the cases are in the vaccine group, there will be significant evidence to
reject the above null hypothesis. If the total number of cases is larger than 44, the maximum
number of cases in the vaccine group that can be observed and still declare success will
increase accordingly.
An internal pilot will be performed in a blinded fashion when ~25% of the 28 cases have
occurred. This assessment will be done to check the assumptions pertaining to the incidence
rate that was used to calculate the projected enrollment. A new sample size projection based
upon the incidence rate (total across treatment groups) that had been observed thus far will
be calculated for planning/budgetary concerns.
In addition, an interim analysis is proposed for the primary endpoint for potential early
study termination if there is overwhelming evidence that vaccine is less efficacious than IG.
The Independent Data Monitoring Committee (IDMC) will be responsible for making the
recommendation on whether or not to continue the study based on the results of the interim
analysis and relevant safety data. The interim analysis will be performed when 14 (~50%) of
the 28 expected cases of laboratory-confirmed clinical hepatitis A have been observed. Using
the same assumptions that were used for the original power calculation, the probability of
meeting the success criteria at the end of the study conditioned on the number of cases that
were observed in the vaccine group for the interim analysis will be calculated. If the
probability is 20% or greater that vaccine will meet the assumed statistical criteria by the
end of the study, then the study will definitely continue. In addition, if after 12 months
from study start, very few cases have been observed, the IDMC will assess the need for study
termination.
